Princess Alexandra Hospital | Metro South Health | ClinicalTrials HQ

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.	B-cell neoplasm, Bites and Stings, Cancer of the Uterine Cervix, Chemically-Induced Disorders, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, Uveal Neoplasms, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, cervix disorder, diffuse large B-cell lymphoma, epithelial neoplasm, eye disorder, female reproductive system disorder, female reproductive system neoplasm, follicular lymphoma, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, in situ carcinoma, injury, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine neoplasm, ocular cancer, poisoning, primitive neuroectodermal tumor, skin disorder, skin neoplasm, squamous cell carcinoma, triple-negative breast carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder, uveal disorder, uveal melanoma	Recruiting	Phase 1	2025-12-24		NCT06022029